Skip to content

Clinical Study on Ultrasound-Guided Microwave/Radiofrequency Ablation for Uterine Fibroids/Adenomyosis

Clinical Study on Ultrasound-Guided Microwave/Radiofrequency Ablation for Uterine Fibroids/Adenomyosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600126248
Enrollment
Unknown
Registered
2026-06-05
Start date
2026-06-05
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

1.Uterine fibroids. 2. Adenomyosis.

Interventions

Sponsors

Beijing Friendship Hospital ,Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1.Diagnosed with uterine fibroids or adenomyosis/adenomyoma via clinical examination, laboratory tests, and imaging (ultrasound ± MRI). 2.Presence of disease-related clinical symptoms with a willingness to undergo treatment; 3.Assessed by the obstetrics and gynaecology/interventional ultrasound team as suitable for ultrasound-guided MWA or RFA treatment. 4.Able to understand the study content and sign the informed consent form, and willing to attend follow-up appointments in accordance with the follow-up plan. 5. Age: Women aged 18–55.

Exclusion criteria

Exclusion criteria: 1.Suspected or confirmed gynaecological malignancy (e.g. uterine sarcoma, endometrial cancer, cervical cancer, etc.) or high-grade cervical lesion. 2.Pregnancy or breastfeeding. 3.Severe coagulation disorder or recent use of anticoagulant/antiplatelet therapy that cannot be discontinued; or active bleeding. 4.Combined severe organ dysfunction (heart, lung, liver, kidney, etc.) or inability to tolerate sedation, analgesia, or anaesthesia. 5.Patients with uncontrolled acute pelvic inflammatory disease. 6.Inability to complete imaging follow-up or expected poor compliance. 7.Other circumstances deemed by the investigator to be unsuitable for enrolment.

Design outcomes

Primary

MeasureTime frame
Lesion and uterine volume;

Secondary

MeasureTime frame
incidence of AE/SAE;

Countries

China

Contacts

Public ContactYu Yang

Beijing Friendship Hospital ,Capital Medical University

ulagirl@126.com+86 10 8083 8576

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026